Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: A meta-analysis of diagnostic accuracy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 6, 2014, Pages 1149-1158

  Shi, Ke Qing ^a   Tang, Jun Zhou ^c   Zhu, Xue Lian ^a   Ying, Li ^a   Li, De Wei ^d   Gao, Jian ^d   Fang, Yu Xiao ^b   Li, Gui Ling ^b   Song, Yi Jiang ^b   Deng, Zhu Jun ^b   Wu, Jian Min ^b   Tang, Kai Fu ^b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Controlled attenuation parameter; FibroScan; Hepatic steatosis; Sensitivity; Specificity

Indexed keywords

ARTICLE; CHRONIC LIVER DISEASE; COCHRANE LIBRARY; CONTROLLED ATTENUATION PARAMETER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ELASTOGRAPHY; EMBASE; FATTY LIVER; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; MEDLINE; META ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STAGING; SYSTEMATIC REVIEW; BIBLIOGRAPHIC DATABASE; CHRONIC DISEASE; COHORT ANALYSIS; ECHOGRAPHY; LIVER DISEASES; PROCEDURES; SEVERITY OF ILLNESS INDEX;

CHRONIC DISEASE; COHORT STUDIES; DATABASES, BIBLIOGRAPHIC; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; HUMANS; LIVER DISEASES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; ULTRASONOGRAPHY;

EID: 84900556498     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12519     Document Type: Article

References (47)

1. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317.
2. David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49: 1904-1912.
3. Valenti L, Fracanzani AL, Bugianesi E etal. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010; 138: 905-912.
4. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832.
5. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49: 1017-1044.
6. Vuppalanchi R, Unalp A, Van Natta ML etal. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin. Gastroenterol. Hepatol. 2009; 7: 481-486.
7. Ratziu V, Charlotte F, Heurtier A etal. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
8. Festi D, Schiumerini R, Marzi L etal. Review article: the diagnosis of non-alcoholic fatty liver disease-availability and accuracy of non-invasive methods. Aliment. Pharmacol. Ther. 2013; 37: 392-400.
9. Petta S, Handberg A, Craxi A. Non invasive indexes for the assessment of patients with non-alcoholic fatty liver disease. Curr. Pharm. Des. 2013; 19: 5193-5218.
10. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J. Hepatol. 2013; 58: 1007-1019.
11. Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur. Radiol. 2011; 21: 87-97.
12. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J. Hepatol. 2009; 51: 433-445.
13. Sasso M, Beaugrand M, de Ledinghen V etal. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med. Biol. 2010; 36: 1825-1835.
14. Kemp W, Roberts S. FibroScan(R) and transient elastography. Aust. Fam. Physician 2013; 42: 468-471.
15. Kumar M, Rastogi A, Singh T etal. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does aetiology affect performance. J. Gastroenterol. Hepatol. 2013; 28: 1194-1201.
16. Masaki K, Takaki S, Hyogo H etal. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol. Res. 2013; 43: 1182-1189.
17. Myers RP, Pollett A, Kirsch R etal. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012; 32: 902-910.
18. Sasso M, Tengher-Barna I, Ziol M etal. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan((R)): validation in chronic hepatitis C. J. Viral Hepat. 2012; 19: 244-253.
19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009; 151: 264-269, W264.
20. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med. Res. Methodol. 2003; 3: 25.
21. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J. Clin. Epidemiol. 2005; 58: 882-893.
22. Hellmich M, Lehmacher W. A ruler for interpreting diagnostic test results. Methods Inf. Med. 2005; 44: 124-126.
23. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann. Intern. Med. 2008; 149: 889-897.
24. Yoneda M. Editorial: utility of controlled attenuation parameter (CAP) measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol. Res. 2013; 43: 1125-1126.
25. Boursier J, Cales P. Controlled attenuation parameter (CAP): a new device for fast evaluation of liver fat? Liver Int. 2012; 32: 875-877.
26. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin. Res. Hepatol. Gastroenterol. 2012; 36: 13-20.
27. Wong GL. Transient elastography: kill two birds with one stone? World. J. Hepatol. 2013; 5: 264-274.
28. Recio E, Cifuentes C, Macias J etal. Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. Eur. J. Gastroenterol. Hepatol. 2013; 25: 905-911.
29. Beaugrand M, Tengher-Barna I, Ziol MNP etal. CAP: a novel non-invasive tool for the evaluation of alcohol induced steatosis [Abstract]. J. Hepatol. 2010; 52: S158-159.
30. Cardoso AC, Sasso M, Miette V, Fournier C, Sandrin L, Beaugrand M. Controlled attenuation parameter: a novel FibroScan®-based tool to detect and quantify steatosis in chronic hepatitis B [Abstract]. Hepatology 2010; 52: 107A.
31. Park PW, Son MS, Yoon H, Yoo JH, Hwang SG, Rim KS. A promising clinical utility of the controlled attenuation parameter (CAP) for noninvasive assessment of steatosis using fibroscan® [Abstract]. J. Gastroenterol. Hepatol. 2012; 27: 239.
32. Recio E, Neukam K, Cifuentes C etal. Interobserver concordance in controlled attenuation parameter (CAP) measurement, a novel tool for the assessment of hepatic steatosis based on transient elastography [Abstract]. J. Hepatol. 2013; 58: S544-545.
33. Kumar M, Rastogi A, Singh T etal. Controlled Attenuation Parameter (CAP) for noninvasive assessment of steatosis using fibroscan in chronic hepatitis B virus infected patients [Abstract]. J. Gastroenterol. Hepatol. 2012; 27: 273.
34. Beaugrand M, de Ledinghen V, Douvin C etal. Validation of controlled attenuation parameter (CAP) as a non-invasive marker of steatosis in 228 patients with chronic liver disease from various causes [Abstract]. J. Hepatol. 2010; 52: S35-36.
35. Sasso MC, Myers RP, Elkashab M. CAP: a vcte (TM)-guided tool for hepatic steatosis detection-preliminaryresults of a multicenter study in overweight and obese patients with chronic liverdisease [Abstract]. Hepatology 2010; 52: 647A.
36. Yilmaz Y, Ergelen R, Akin H, Imeryuz N. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. Eur. J. Gastroenterol. Hepatol. 2013; 25: 1330-1334.
37. Carvalhana S, Leitão J, Alves AC, Bourbon M, CortezPinto H. Controlled attenuation parameter (CAP) for non-invasive assessment of liver steatosis in the general population: correlation with ultrasound (us) and fatty liver index (FLI) [Abstract]. J. Hepatol. 2013; 58: S533-534.
38. Enooku K, Tateishi R, Fujiwara N etal. Non-invasive measurement of liver steatosis by controlled attenuation parameter (CAP) using Fibroscan® in patients with nonalcoholic fatty liver disease (NAFLD) [Abstract]. J. Hepatol. 2013; 58: S536-537.
39. Wong GlH, Wong VWS, Lai JWY, Chim AML, Chan HLY. Controlled attenuation parameter (CAP) of transient elastography is an accurate non-invasive assessment of hepatic steatosis [Abstract]. J. Gastroenterol. Hepatol. 2012; 27: 239-240.
40. de Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012; 32: 911-918.
41. Friedrich-Rust M, Romen D, Vermehren J etal. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur. J. Radiol. 2012; 81: e325-331.
42. Recio E, Cifuentes C, Macias J etal. Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. Eur. J. Gastroenterol. Hepatol. 2013; 25: 905-911.
43. Day CP. Clinical spectrum and therapy of non-alcoholic steatohepatitis. Dig. Dis. 2012; 30 (Suppl. 1): 69-73.
44. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment. Pharmacol. Ther. 2012; 36: 815-823.
45. Havre RF, Elde E, Gilja OH etal. Freehand real-time elastography: impact of scanning parameters on image quality and in vitro intra- and interobserver validations. Ultrasound Med. Biol. 2008; 34: 1638-1650.
46. de Ledinghen V, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int. 2010; 30: 1043-1048.
47. de Ledinghen V, Wong VW, Vergniol J etal. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R). J. Hepatol. 2012; 56: 833-839.